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Short title: Recessive coding causes of developmental disorders 
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Large-scale sequencing can help uncover the genetic architecture of rare diseases. We 
estimated the genome-wide contribution of recessive coding variation from 6,040 exome-
sequenced families from the Deciphering Developmental Disorders study. The proportion 
of cases attributable to recessive coding variants was 3.6% in patients of European 
ancestry, compared to 50% explained by de novo coding mutations. It was higher (31%) in 
patients with Pakistani ancestry, due to elevated autozygosity. Half of this recessive burden 
is attributable to known genes. We identified two genes not previously associated with 
recessive developmental disorders, EIF3F and KDM5B. Our results suggest that recessive 
coding variants account for a small fraction of currently undiagnosed individuals, and that 
the role of pathogenic noncoding variants, incomplete penetrance, and polygenic 
mechanisms need further exploration. 
 
Genetic studies of rare diseases traditionally followed a phenotype-driven search for a shared 
genetic diagnosis in multiple individuals with a clinically similar presentation. Large-scale 
sequencing studies of more phenotypically heterogeneous patients have inverted this process, 
and have demonstrated the power of unbiased, genotype-first discovery of new disease genes (1±
3). It is also possible to use the same datasets to characterise the overall genetic architecture of 
such disorders. For example, analyses of one such cohort, the Deciphering Developmental 
Disorders study (DDD) (4), discovered new dominant disease genes (1), estimated the fraction of  
patients with a causal de novo mutation in both known and as-yet undiscovered dominant genes 
(40-45%), and made predictions about the prevalence of such disorders (5). 
 
Extending our analyses to other modes of inheritance may help design gene discovery studies 
and inform counselling about recurrence risk. It has been posited that there are thousands of 
recessive genes yet to be discovered (6, 7), which could imply that recessive genes explain a 
large fraction of undiagnosed rare disease cases. However, attempts to estimate the prevalence of 
recessive disorders have been restricted to known disorders (8) or known pathogenic alleles (9). 
There has been no systematic attempt to quantify the overall recessive burden using large-scale 
sequencing data and a robust statistical and computational genetic framework.  
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We describe an analysis of autosomal recessive coding variants in 6,040 exome-sequenced trios 
from the British Isles, recruited as part of the DDD study. We use a probabilistic method for 
identifying robust new recessive genes (10), in contrast to the heuristic filtering methods 
commonly applied (e.g. (11±13)). We extend this to estimate the overall burden of recessive 
causation in this cohort, and compare it between patients with different ancestries. Our approach 
overcomes drawbacks of previously published methods (3, 10) that do not provide well-
calibrated estimates of the exome-wide burden of recessive disease.  
 
Results 
Genome-wide recessive burden  
We hypothesized there should be a burden of biallelic genotypes predicted either to cause loss-
of-function (LoF) or functional impairment to a protein. For each of three possible genotype 
configurations (LoF on both alleles, damaging missense on both alleles, or one on each allele), 
we compared the number of observed rare (minor allele frequency, MAF, <1%) biallelic 
genotypes in our cohort to the number expected by chance given the population frequency of 
such variants and the gene-specific fraction of autozygous individuals (14). Because the expected 
number is sensitive to inaccuracy in population frequency estimates of very rare variants in 
broadly-defined ancestry groups, we focused our analysis on the largest two subsets of the cohort 
with homogenous ancestry (Fig. S1), corresponding in a principal components analysis using 
1000 Genomes to Great British individuals and Punjabis from Lahore, Pakistan (Fig. S2). We 
refer to these subsets as having European Ancestry or Pakistani Ancestry from the British Isles 
(EABI, PABI). 
 
We evaluated three methods for calculating the expected number of biallelic genotypes, using 
synonymous variants as a control. Firstly, we used the non-Finnish Europeans and South Asians 
from the Exome Aggregation Consortium (ExAC) (15) to estimate the allele frequencies for 
EABI and PABI respectively, as described previously (10). However, we found that the total 
observed number of biallelic synonymous genotypes was lower than the expected number (Fig. 
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S3). This is due to a combination of differences in sequence coverage, quality control, and 
ancestry between DDD and ExAC, and the lack of phased, individual-specific data in ExAC 
needed to avoid double-counting variants on the same haplotype within a gene. Secondly, we 
considered an approach (3) that uses per-gene mutation rates. While it was well-calibrated for 
individual genes, this method produced a significant underestimate of the total expected number 
of synonymous biallelic genotypes (Fig. S3). Finally, we used the phased haplotypes from 
unaffected DDD parents to estimate the expected number of biallelic genotypes (14). With this 
method, the number of observed biallelic synonymous genotypes closely matched what we 
would expect by chance (ratio=0.997 for EABI and 1.003 for PABI; Poisson p=0.6 and 0.4) (Fig. 
1A), so we used it henceforth. 
 
We observed no significant burden of biallelic genotypes of any consequence class in 1,389 
probands with a likely diagnostic de novo mutation, inherited dominant variant or X-linked 
variant, consistent with those probDQGV¶ SKHQRW\SHV EHLQJ IXOO\ H[SODLQHG E\ SUHYLRXVO\
identified variants. We therefore evaluated the recessive coding burden in 4,318 EABI and 333 
PABI probands whom we deemed more likely to have a recessive cause of their disorder because 
they did not have a likely dominant or X-linked diagnosis (4), or had at least one affected sibling, 
or >2% autozygosity. As expected due to their higher autozygosity (Fig. S4), PABI individuals 
had more rare biallelic genotypes than EABI individuals (Fig. 1). Ninety-two percent of the 
likely damaging rare biallelic genotypes observed in PABI samples were homozygous (rather 
than compound heterozygous), versus only 28% for the EABI samples. We observed a 
significant enrichment of biallelic LoF genotypes above chance expectation in both the EABI 
and PABI groups (~1.4-fold enrichment in each; Poisson p=3.5×10-5 for EABI, p=9.7×10-7 for 
PABI). We also observed a smaller enrichment of biallelic damaging missense genotypes which 
was nominally significant in the EABI group (Poisson p=0.03), as well as a significant 
enrichment of compound heterozygous LoF/damaging missense genotypes in the EABI group 
(1.4-fold enrichment; Poisson p=6×10-7). In the EABI group, the enrichments became stronger 
and more significant at lower MAF, but the absolute number of excess variants fell slightly (Fig. 
S5). Thus, plausibly pathogenic variants are concentrated at rarer MAF, but some do rise to 
higher frequencies.  
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We found that particular gene sets showed a higher burden of damaging biallelic genotypes 
amongst the 4,318 EABI and 333 PABI undiagnosed probands. A set of 903 clinically-curated 
DD-associated recessive genes showed very strong enrichment of damaging biallelic genotypes 
(1.7-fold; Poisson p=6×10-18 for EABI and PABI combined). Indeed, 48% of the observed 
excess of damaging biallelic genotypes lay in these known genes. We also found a significant 
enrichment of damaging biallelic genotypes in 3371 genes annotated as having high probability 
of being intolerant of LoFs in the recessive state (pRec>0.9) (15) (1.2-fold; Poisson p=2×10-8), 
even after excluding the known recessive genes used to train the model (1.1-fold; Poisson 
p=4×10-4), and in 189 genes that were sub-viable when knocked out homozygously in mice (16) 
(1.8-fold; Poisson p=2×10-3). By contrast, we did not observe any recessive burden in 243 DD-
associated genes that act by a dominant LoF mechanism, nor in genes predicted to be intolerant 
of heterozygous LoFs (probability of LoF intolerance, pLI, >0.9) in ExAC. We did not see 
excess recessive burden in the diagnosed probands in any of these gene sets (Poisson p>0.05). 
 
We developed a method to estimate the proportion of probands who have a diagnostic variant in 
a particular genotype class (14). In contrast to our previously published approach (5), this 
method accounts for the fact that a fraction of the variants expected by chance are actually causal 
(Fig. S6); thus, it gives higher estimates than previously reported for the proportion of the cohort 
with causative de novo mutations. We estimated that 3.6% (~205) of the EABI probands have a 
recessive coding diagnosis, compared to 49.9% (~2836) with a de novo coding diagnosis. In the 
PABI subset, recessive coding genotypes likely explain 30.9% (~110) of the individuals, 
compared to 29.8% (~106) for de novo coding mutations. The contribution from recessive 
variants was nearly four times as high in EABI probands with similarly affected siblings than 
those without affected siblings (12.0% versus 3.2%), and highest in PABI probands with high 
autozygosity (47.1%) (Fig. 2; Table S2). In contrast, it did not differ significantly between PABI 
probands with low autozygosity and EABI probands.  
 
Discovery of new recessive disease genes 
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To discover previously unidentified recessive genes, we next tested each gene for an excess of 
biallelic genotypes in undiagnosed probands from either EABI alone or EABI+PABI (Table S3) 
(14). Three genes passed stringent Bonferroni correction (binomial p<3.4×10-7, accounting for 8 
tests for each of 18,630 genes): EIF3F, KDM5B and THOC6, of which the last is an established 
recessive DD-associated gene (17). Thirteen additional genes had p<10-4 (Table 1).  Eleven of 
these are known recessive DD-associated genes, and the distribution of p-values for all such 
known genes was shifted lower than that of all other genes (Kolmogorov-Smirnov test; p<1×10-
15; Fig. S7). These observations validate our gene discovery approach, and suggest that our 
genome-wide significance threshold is conservative. 
 
We observed five probands with an identical homozygous missense variant in EIF3F (binomial 
p=1.2×10-10) (ENSP00000310040.4:p.Phe232Val), predicted to be deleterious by SIFT, 
polyPhen and CADD. An additional four individuals in the DDD cohort were also homozygous 
for this variant but had been excluded from our discovery analysis for various reasons (Table 
S4). All probands had European ancestry and low overall autozygosity, and none of them (apart 
from the pairs of siblings) were related (kinship<0.02). In the gnomAD resource of population 
variation (http://gnomad.broadinstitute.org/), this variant (rs141976414) has a frequency of 
0.12% in non-Finnish Europeans, and no homozygotes were observed. The observation that this 
single missense variant is driving all of the signal in EIF3F probably reflects the fact that it is 
one of the most common variants in the gene. EIF3F is essential in several cancer cell lines (18, 
19), so the biallelic knockout is likely to be lethal to humans; consistent with this, LoFs in this 
gene in gnomAD are very rare (MAF<0.01%). 
 
All nine individuals homozygous for the EIF3F variant had ID and six had seizures (Table S4). 
Those for whom photos were available did not have a distinctive facial appearance (Fig. S8). 
Features observed in three or more unrelated individuals were behavioral difficulties and 
sensorineural hearing loss. One patient had skeletal muscle atrophy (Fig. S8), which is only 
reported in one other proband in the DDD study. This is notable because in mice, Eif3f has been 
shown to play a role in regulating skeletal muscle size via interaction with the mTOR pathway 
(20).  
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EIF3F encodes the F subunit of the mammalian eIF3 (eukaryotic initiation factor) complex, 
a negative regulator of translation. The genes encoding eIF2B subunits have been implicated in 
severe autosomal recessive neurodegenerative disorders (21). The secondary structure, domain 
architecture and 3D fold of EIF3F is conserved between species but sequence similarity is low 
(29% between yeast and humans) (Fig. 3A). The conserved Phe232 side chain mutated in our 
patients is buried (solvent accessibility 0.7%) and likely plays a stabilizing role (Fig. 3B). The 
loss of the aromatic side chain in the Phe232Val variant would likely disrupt protein stability. It 
is currently unknown how the Phe232Val variant affects EIF3F function and causes DD.  
 
Another recessive gene we identified was KDM5B (binomial p=1.1×10-7) (Fig. 4), encoding a 
histone H3K4 demethylase. Other H3K4 methylases and demethylases are known to cause 
neurodevelopmental disorders (22±24). Three probands had biallelic LoFs passing our filters, 
and we subsequently identified a fourth who was compound heterozygous for a splice site variant 
and large gene-disrupting deletion. While our paper was under review, Faundes et al. (25) 
reported biallelic LoFs in KDM5B in three DD patients, including two of ours; our result 
provides robust statistical evidence that these are pathogenic. KDM5B is also enriched for de 
novo mutations in the DDD cohort (5) (binomial p=5.1×10-7). Additionally, we saw nominally 
significant over-transmission of LoF variants from the parents, who were almost all unaffected 
(p=0.002 including all families; transmission-disequilibrium test; Table S5). There was no 
evidence for a parent-of-origin bias in which parent transmitted the LoF.  
 
We considered the possibility that all the KDM5B LoFs observed in probands might be, in fact, 
acting recessively and that the probands with apparently monoallelic LoFs had a second coding 
or regulatory hit on the other allele. However, we found no evidence supporting this hypothesis 
(see (14) and Fig. S9), nor of potentially modifying coding variants in likely interactor genes. 
There was also no evidence from the annotations in Ensembl or GTex data 
(https://gtexportal.org/home/) that the pattern could be explained by some LoFs avoiding 
nonsense-mediated decay (Fig. 4B). We searched for potential modifying epimutations, but 
found none  (Fig. S10). These lines of evidence suggest that heterozygous LoFs in KDM5B are 
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pathogenic with incomplete penetrance, while homozygous LoFs are likely fully penetrant. 
Genome-wide analysis of DNA methylation levels in whole blood found no significant 
differences between probands with different types of KDM5B mutations or between these and 
controls (Fig. S11). 
 
The four individuals with biallelic KDM5B variants have ID and variable congenital 
abnormalities (Table S6), in line with those seen in other disorders of the histone machinery (26). 
Affected individuals have a distinctive facial appearance with narrow palpebral fissures, arched 
or thick eyebrows, dark eyelashes, a low hanging columella, smooth philtrum and a thin upper 
vermillion border (Fig. 4C). However, in contrast to other disorders of the histone machinery, 
there was no consistent growth pattern. Other than ID, there were no consistent phenotypes or 
distinctive features shared between the biallelic and monoallelic individuals, or within the 
monoallelic group (Table S6).  
 
Discussion 
We found the contributions of de novo and recessive coding variants were approximately equal 
among DDD probands with Pakistani ancestry (both ~30%), but recessive causes contribute less 
than a tenth of the disease burden of dominant causes in the probands with European ancestry 
(3.6% vs 49.9% respectively). Our results are in line with previous reports of a low fraction of 
recessive diagnoses in European cohorts (3, 4, 27), but in contrast to those studies, our estimates 
include the recessive contribution in as-yet-undiscovered genes and are therefore unbiased. 
While it has been hypothesised that there are many more recessive DD-associated genes to be 
discovered (6, 28), our analyses suggest that the cumulative impact of these discoveries on 
diagnostic yield will be modest in outbred populations. 
   
Our use of DDD parental allele frequencies allowed us to carry out a properly calibrated burden 
analysis (Fig. S3), but does have caveats. Any enrichment in damaging coding variants in DDD 
parents compared to the general population will result in overestimates of the population 
frequency of such variants, as will the systematic difference between the true allele frequency of 
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a very rare variant and its estimate from a finite sample size (15). These effects could cause us to 
slightly underestimate the overall burden. Reassuringly, our estimate in the PABI subset (30.9%) 
is close to the 31.5% reported by genetics clinics in Kuwait (29), which has a similar level of 
consanguinity (30).  
 
Our results have clinical value because they can be used to improve recurrence risk estimates for 
families with a particular ancestry and pattern of inheritance, but without a molecular diagnosis. 
Because our exact burden results derive from the patient population within the DDD study, 
extrapolating more widely requires some care. For example, the proportion of all DD patients in 
the British Isles with a recessive coding cause is probably higher than our estimate because some 
recessive DDs are relatively easily diagnosed through current screening and diagnostic practice 
(e.g. metabolic disorders) and therefore are less likely to be recruited to a research study. 
Furthermore, while the ascertainment of the DDD study is likely to be a reasonable proxy for 
undiagnosed patients from genetics clinics in the UK, country-specific properties of medical 
practice and levels of consanguinity may make the exact estimates less applicable elsewhere.   
 
Recent papers have described the population structure and characteristics of South Asian 
populations and highlighted their potential for recessive disease gene discovery (31). Despite this 
expectation, and the substantially higher burden of recessive causation in the PABI subset (Fig. 
2), they contributed little to our new gene discovery. This was partially due to modest sample 
size (which also explains the wide confidence intervals in Table S2) but was exacerbated by the 
consistent overestimation of rare variant frequencies.  
 
Because damaging biallelic genotypes in EIF3F and KDM5B result in nonspecific and 
heterogeneous phenotypes, they are less likely to have been found by typical studies. KDM5B is  
unusual for a recessive gene because heterozygous LoFs appear to be pathogenic with 
incomplete penetrance. Several de novo missense and LoF mutations in KDM5B had previously 
been reported in individuals with autism or  ID (32, 33), but also  in unaffected individuals (32). 
The other genes encoding H3K4 methylases and demethylases reported to cause DD are mostly 
dominant (24) and typically have a pLI score >0.99 and a very low pRec, in contrast to KDM5B 
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(pLI=5×10-5; pRec>0.999). LoFs in some other dominant ID genes appear to be incompletely 
penetrant (34), as do several microdeletions (35). The evidence suggests that biallelic LoFs in 
KDM5B are fully penetrant in humans, but interestingly, the homozygous knockout shows 
incomplete penetrance in mice, with only one strain presenting with neurological defects (36, 
37). Until further studies clarify the true inheritance pattern of KDM5B-related disorders, caution 
should be exercised when counselling families about the clinical significance of heterozygous 
variants in this gene.  
 
 Our results suggest that identifying all recessive DD genes would allow us to diagnose 5.2% of 
the EABI+PABI subset of DDD, whereas identifying all the dominant DD genes would yield 
diagnoses for 48.6%. The high proportion of unexplained patients even amongst those with 
affected siblings or high consanguinity suggests that future studies should investigate a wide 
range of modes of inheritance including oligogenic and polygenic inheritance as well as 
noncoding recessive variants.   
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Tables 
Table 1: Genes enriched for damaging biallelic coding genotypes with p<1×10-4 (for eight tests; 
see (14)). Shown are the number of observed biallelic genotypes of different consequence 
classes, the lowest p-value out of the eight tests (achieved using EABI alone for all genes except 
for VPS13B), details of the corresponding test, and the p-value for phenotypic similarity for the 
relevant probands (10). Known recessive DD genes from the DDG2P list are indicated 
(http://www.ebi.ac.uk/gene2phenotype/).  
 
 
 
 
 
 
 
 
 
 
gene 
Biallelic genotypes counts for 
EABI (PABI if >0) 
p-value - 
genotype 
p-value - 
phenotype 
Consequence class 
for most 
Note 
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LoF 
LoF/ 
damaging 
missense 
damaging 
missense 
significant test 
EIF3F 0 0 5 1.2E-10 0.72 damaging missense 
two probands had another affected sibling, 
both of whom were homozygous for the 
same variant 
THOC6 0 1 3 4.4E-09 6.0E-05 
LoF + 
LoF/damaging 
missense + 
damaging missense 
known recessive gene 
KDM5B 3 0 0 1.1E-07 0.53 LoF 
previously reported as dominant gene; a 
fourth proband is compound heterozygous 
for a splice variant and CNV 
CNTNAP1 2 (1) 1 0 (1) 1.8E-06 0.02 
LoF+LoF/damaging 
missense 
known recessive gene 
KIAA0586 5 1 1 1.9E-06 0.05 LoF 
known recessive gene; two probands have 
affected sibs, and both share the variants 
NALCN 1 2 0 2.4E-06 0.37 
LoF+LoF/damaging 
missense 
known recessive gene; one proband has an 
affected sib who shares the variants 
PIGN 0 3 1 2.5E-06 0.10 
LoF + 
LoF/damaging 
missense + 
damaging missense 
known recessive gene; one proband has an 
affected sib who shares the variants 
ST3GAL5 0 (1) 2 0 2.7E-06 0.09 
LoF+LoF/damaging 
missense 
known recessive gene 
ATAD2B 1 1 0 3.6E-06 0.88 
LoF+LoF/damaging 
missense 
one of our probands has an affected sib 
who shares the variants 
LZTR1 0 3 0 5.6E-06 0.06 
LoF+LoF/damaging 
missense 
one of our probands has an affected sib 
who does not share both variants, so 
causality is dubious ;dominant missense 
mutations cause Noonan syndrome(38)  
LINS 2 0 0 8.2E-06 0.74 LoF 
one proband has affected sib who shares 
the variant; putative recessive gene(39, 40) 
POLR1C 0 1 2 1.4E-05 0.42 
LoF + 
LoF/damaging 
missense + 
damaging missense 
known recessive gene 
MMP21 0 2 0 1.4E-05 2.0E-03 
LoF+LoF/damaging 
missense 
known recessive gene 
MAN1B1 1 1 0 1.5E-05 0.62 
LoF+LoF/damaging 
missense 
known recessive gene 
VPS13B 2 (1) 1 2 2.8E-05 0.05 LoF known recessive gene 
UBA5 0 2 1 3.7E-05 0.84 
LoF+LoF/damaging 
missense 
known recessive gene 
 
 
Figures 
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Fig. 1: Enrichment of damaging biallelic genotypes in DDD probands. Number of observed and 
expected biallelic genotypes per individual for all genes in A) undiagnosed EABI and PABI 
probands, and B) different subsets of undiagnosed probands (see (14)). Samples sizes are 
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indicated in parentheses in the keys. Nominally significant p-values from a Poisson test of 
enrichment are shown.  
 
 
Fig. 2: Proportion of probands explained by recessive coding variants versus de novo coding 
mutations. Left: number of probands grouped by diagnostic category. The inherited dominant 
and X-linked diagnoses (narrow pink bar) include only those in known genes, whereas the 
proportion of probands with de novo and recessive coding diagnoses was inferred as described in 
(14). Right: the proportion of probands in various EABI and PABI subsets inferred to have 
diagnostic variants in the indicated classes. 
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Fig. 3: Predicted effects of a pathogenic recessive missense variant in EIF3F. A) Section of the 
amino acid sequence logo for EIF3F where the strength of conservation across species is 
indicated by the size of the letters. The sequence below represents the human EIF3F. Boxed 
characters are the aromatic residues conserved between humans and yeast and proximal in space 
to Phe232. B) Structure of the section of EIF3F containing the Phe232Val variant, highlighted in 
green. Amino acids conserved between yeast and human sequences as highlighted in panel A are 
shown in grey. See (14) for details of structure prediction. 
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Fig. 4: KDM5B is a recessive DD gene in which heterozygous LoFs are incompletely penetrant. 
A) Summary of damaging variants found in KDM5B. B) Positions of likely damaging variants 
found in this and previous studies in the longest annotated transcript of KDM5B, 
ENST00000367264.2 (introns not to scale). Colors correspond to those shown in (A). Note the 
lack of obvious differences in the spatial distribution of de novo versus monoallelic or biallelic 
inherited LoFs within the gene. Two large deletions have been omitted. All variants are listed in 
Table S6. C) Anterior-posterior facial photographs of two of the individuals with biallelic 
KDM5B variants. Informed consent was obtained to publish these.  
